Non-Hematologic Malignancy Clinical Trial
Official title:
Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records (GRECO)
To document the clinical outcomes of cancer patients who received the Guardant360® test and agree to share their records with Guardant Health.
This is an observational study of clinical outcomes to be conducted in the United States. Patients with a diagnosis of Stage 3-4 advanced cancer who possess specific pathway mutations identified by the Guardant360® test will be eligible to enroll in the study. Patients will be recruited by telephone or email and/or through the Guardant Health Patient Portal to determine interest in the study. Should patients be interested in contributing to this registry study, they will be prompted to consent via a commercial service for patients to request, manage, and view their medical records. Enrolled participants will be requested to release copies of their medical records for review by the principal investigator. Study adminsitrators will abstract participant demographics, cancer-related therapies, and clinical outcomes for analysis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05077384 -
Open-label Study of Surufatinib in Japanese Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02412722 -
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04285242 -
Metabolic and Immunological Phenotyping in Patients With Cancer
|
||
| Not yet recruiting |
NCT05968170 -
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
|
N/A |